Document:

EX-10.8(a)

 Exhibit 10.8(a) 

June 1, 2013 
 Rabar Market Research, Inc. 

10 Bank Street, Suite 830 
 White Plain, New York 10606-1933 

Attn: Mr. Paul Rabar 
  

	 	Re:	Management Agreement Renewals  

 Dear Mr. Rabar 

We are writing with respect to your management agreements concerning the commodity pools to which reference is made below (the “Management
Agreements”). We are extending the term of the Management Agreements through June 30, 2014 and all other provisions of the Management Agreements will remain unchanged. 

 

	 	•	 	Rabar Master Fund L.P. 

  

	 	•	 	Westport Futures Fund L.P. 

  

	 	•	 	Tidewater Futures Fund L.P. 

 Please acknowledge receipt of this modification by signing one copy of this
letter and returning it to the attention of Mr. Damian George at the address above or fax to 212-296-6868. If you have any questions I can be reached at 212-296-1292. 
  

					
	Very truly yours,	  	
		
	CERES MANAGED FUTURES LLC	  	
			
	By:	 	 /s/ Damian George
	  	
		 	Damian George	  	
		 	Chief Financial Officer and Director	  	
		
	JOHN W. HENRY & COMPANY, INC	  	
			
	By:	 	 /s/ Paul Rabar
	  	
			
	Print Name:	 	 Paul Rabar
	  	
		
	DG/srEX-10.26

 Exhibit 10.26 

REVANCE THERAPEUTICS, INC. 

2014 MANAGEMENT BONUS PROGRAM 
 Upon the
recommendation of the Compensation Committee of the Board of Directors of Revance Therapeutics, Inc. (the “Company”), the Company’s Board of Directors on March 17, 2014, approved the corporate objectives for the Company’s
named executive officers relating to the Company’s 2014 cash performance bonus program (the “2014 Bonus Program”). 
 The 2014 Bonus Program
is designed to reward, through the payment of annual cash bonuses, the Company’s executive officers for the Company’s performance in meeting key corporate objectives for 2014 and for the Company’s named executive officers other than
the Chief Executive Officer, individual performance in meeting specified corporate goals for the year. The actual cash bonus awarded in any year, if any, may be more or less than each executive’s annual target bonus, and shall be subject to
approval by the Compensation Committee or the Board of Directors. For the Company’s named executive officers, the target bonuses, and whether or not a bonus is paid in any year, is within the discretion of the Compensation Committee. 

The 2014 corporate objectives relate to product development milestones, including successful completion of the Company’s ongoing RT002 Phase 1/2
glabellar lines clinical trial (30% weighting) and achievement of positive efficacy results from the planned RT001 Phase 3 crow’s feet lines clinical trial in the United States (40% weighting) and the achievement of specified financing
objectives (30% weighting). 
 Our Chief Executive Officer’s cash bonus under the 2014 Bonus Program will be entirely based on the achievement of the
2014 corporate objectives. The cash bonus for all other named executive officers shall be based on the achievement of his or her individual performance goals (25% weighting) and on the achievement of the 2014 corporate objectives (75% weighting).
The named executive officers’ actual bonuses may exceed 100% of target in the event performance exceeds the predetermined goals.EX-10.31

 Exhibit 10.31 

March 3, 2014 
 Angus C. Russell 

1366 John Anderson Drive 
 Ormond Beach, FL 32176 

 

	 	Re:	Service on Board of Directors of Revance Therapeutics, Inc. 

 Dear Angus: 

On behalf of Revance Therapeutics, Inc. (the “Company”), I am pleased to invite you to join the Company’s Board of Directors (“Board”)
under the terms and conditions set forth herein. 
 The Company agrees to appoint you (subject to Board approval), and you agree to serve, as Chairman on
the Board effective as of March 4, 2014 (the “Effective Date”). You will serve as a Director from the Effective Date until you voluntarily resign or are removed from the Board (the “Term”). As a Director, you will be
expected to participate in regularly scheduled meetings, which are expected to occur approximately four times per year, as well as special meetings of the Board. You will devote your best efforts and apply your professional expertise to the
interests and welfare of the Company, and will be expected to comply with all of your legal obligations to the Company as a Director (e.g., fiduciary duties). 

During the Term, you will receive quarterly payments of $16,000 as compensation for your services as a Director, payable on the terms set forth in the
Company’s Non-Employee Director Compensation Policy (the “Policy”). In the event that you serve on a Board committee, you may be eligible to receive additional compensation for such service, per the Policy. 

Pursuant to the Policy, you will also receive a non-qualified stock option to purchase 18,000 shares of the Company’s common stock (the
“Option”) under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”). The Option will vest on the one year anniversary of the date of the grant subject to your Continuous Service (as defined in the 2014 Plan) and shall
be governed in all respects by the 2014 Plan documents and applicable Option agreement. Subject to your Continuous Service as a non-employee member of the Board, you will be eligible for additional grants, as set forth in the Policy. 

The Company will reimburse you for reasonable travel and other incidental expenses approved by the Company, so long as you provide the Company with
appropriate receipts or other relevant documentation. You are not an employee of the Company and have no authority to obligate the Company by contract or otherwise. You will not be eligible for any employee benefits, nor will the Company make
deductions from any amounts payable to you for taxes. Any taxes shall be solely your responsibility. 

 You shall receive indemnification subject to the terms of the Company’s form of indemnification agreement,
which shall be provided to you under separate cover. 
 You represent and warrant that your services as a Director of the Company will not conflict with,
and will not be constrained by, any prior or current agreement or relationship between you and any third party. 
 This letter agreement, together with your
indemnification agreement and any applicable Option agreements, constitutes the entire agreement between you and the Company with respect to your service as a Director and supersedes any prior agreement, promise, or representation (whether written
or oral) between you and the Company with regard to this subject matter. This letter agreement is entered into without reliance on any promise, representation, statement or agreement other than those expressly contained herein, and it cannot be
modified or amended except in a writing signed by the party or parties affected by such modification or amendment. All questions concerning the construction, validity and interpretation of this letter agreement will be governed by the law of the
State of California as applied to contracts made and to be performed entirely within California. 
 Please note that, in the interest of time, this letter
agreement is being presented to you prior to the Board’s formal appointment of you to the Board and adoption of the other terms of this letter agreement. As a result, the effectiveness of the terms of this letter agreement shall be conditioned
upon the Board’s appointment of you to the Board, acting in their sole discretion. 
 We are all delighted to be able to extend you this offer and look
forward to working with you. To indicate your acceptance of the Company’s offer, please sign and date this letter agreement, complete the enclosed Form W-9, and return it to the attention of Lauren Silvernail, the Chief Financial Officer of the
Company. 
 Sincerely, 
 REVANCE
THERAPEUTICS, INC. 
  

	
	 /s/ L. Daniel Browne

	 L. Daniel Browne

	 Chief Executive Officer

 AGREED: 
  

			
	 /s/ Angus C. Russell

	 Angus C. Russell

	 Date:
	 	     March 3,
2014            

  
 2.EX-10.6(a)

 Exhibit 10.6(a) 
 June 1, 2013 
 Aspect Capital Ltd. 
 Nations House — 8th Floor 
 103 Wigmore Street 

London W1U 1QS, U.K. 
 Attention:
Mr. Anthony Todd, CEO 
 Re: Management Agreement Renewals 
 Dear Mr. Todd: 
 We are writing with respect to your management agreements concerning the
commodity pools to which reference is made below (the “Management Agreements”). We are extending the term of the Management Agreements through June 30, 2014 and all other provisions of the Management Agreements will remain unchanged.

  

	 	•	 	 Global Diversified Futures Fund L.P. 

  

	 	•	 	 Diversified 2000 Futures Fund L.P. 

  

	 	•	 	 Tactical Diversified Futures Fund L.P. 

  

	 	•	 	 CMF Aspect Master Fund L.P. 

  

	 	•	 	 Institutional Futures Portfolio LP 

  

	 	•	 	 Global Futures Fund Ltd. 

 Please acknowledge receipt of this modification by signing one copy of this letter and returning it to the attention of Mr. Damian George at the address above or fax to 212-296-6868. If you have any
questions I can be reached at 212-296-1292. 
 Very truly yours, 

 

					
	 CERES MANAGED FUTURES LLC
	 	
			
	By:	 	 /s/ Damian George
	 	
		 	 Damian George 
	 	
		 	Chief Financial Officer & Director	 	
			
	By:	 	 /s/ Kenneth Hope
	 	
		 	Print Name: Kenneth Hope	 	

 DG/srEX-10.7(a)

 Exhibit 10.7(a) 
 June 1, 2013 
 Eckhardt Trading Company 

1314 North Dearborn Parkway 
 The Carriage House

 Chicago, Illinois 60610 
 Attention:
Ms. Audrey L. Gale 
 Re: Management Agreement Renewal 
 Dear Ms. Gale: 
 We are writing with respect to your management agreement concerning the
commodity pool to which reference is made below (the “Management Agreement”). We are extending the term of the Management Agreement through June 30, 2014 and all other provisions of the Management Agreement will remain unchanged.

  

	 	•	 	 CMF Eckhardt Master Fund L.P. 

  

	 	•	 	 Diversified 2000 Futures Fund L.P. 

  

	 	•	 	 Diversified Multi-Advisor Futures Fund L.P. 

  

	 	•	 	 Diversified Multi-Advisor Futures Fund L.P. II 

 Please acknowledge receipt of this modification by signing one copy of this letter and returning it to the attention of Mr. Damian George at the address above or fax to 212-296-6868. If you have any
questions I can be reached at 212-296-1292. 
 Very truly yours, 

 

					
	CERES MANAGED FUTURES LLC	 	
			
	By:	 	 /s/ Damian George
	 	
		 	 Damian George 
	 	
		 	Chief Financial Officer and Director	 	
		
	ECKHARDT TRADING COMPANY	 	
			
	By:	 	 /s/ Audrey Gale
	 	
		 	Print Name: Audrey Gale	 	

 DG/sr

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]